<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03098420</url>
  </required_header>
  <id_info>
    <org_study_id>F160421006</org_study_id>
    <nct_id>NCT03098420</nct_id>
  </id_info>
  <brief_title>Dose Escalation of Dexamethasone to Increase Duration of Transversus Abdominal Plane Block Following Cesarean Section</brief_title>
  <official_title>Dose Escalation of Dexamethasone to Increase Duration of Transversus Abdominal Plane Block Following Cesarean Section: A Prospective Randomized Double-Blinded Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to improve the care of the obstetric population after cesarean section and
      improve total patient satisfaction by improving post-surgical pain control with the use of
      dexamethasone in combination with bilateral TAP blocks. The investigators will utilize a
      dose-escalation of dexamethasone in the TAP block to observe its effects at specific small
      doses. It is the hope of the investigator that the studied technique would become utilized
      routinely for the obstetric population following cesarean section.

      The investigators hope to show that the addition of dexamethasone in bilateral TAP blocks
      will prolong the duration of the block in a dose-dependent fashion. The investigators hope to
      improve post-operative pain following cesarean section, increase duration of TAP block with
      use of dexamethasone, decrease overall pain scores in the first 24-48 hours, and decrease
      opioid requirements after cesarean section.

      The primary endpoint will be estimation of duration of TAP block, being assessed within 48
      hours after surgery. Secondary endpoints will include pain scores both in PACU and on the
      floor, average pain scores, time until first opioid administration, total opioid consumption
      in first 48 hours, use of PONV medications, and overall patient satisfaction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Preoperatively: informed consent will be obtained by a member of this study. The patients
      will be screened for inclusion/exclusion criteria on day of procedure, and then the
      participants will be randomized to one of three groups.

      Intraoperatively: The anesthesia team involved with care of patient in the operating room
      will provide routine anesthesia care during the cesarean section including neuraxial
      anesthesia with intrathecal bupivacaine and morphine.

      After completion of the procedure, the patients will receive bilateral TAP block procedure
      while still in OR. All blocks will include 20mL of 0.5% ropivacaine, and the patients will be
      randomly assigned a specific dose of dexamethasone at 0mg (given normal saline as control),
      2mg, or 4mg. The resident or attending physician supervising the block will be investigators
      of the study, and they along with the residents performing the blocks will be blinded to the
      amount of dexamethasone in the injectate.

      Postoperatively: The patients will then be monitored in the PACU for approximately 30-60
      minutes and then subsequently monitored on an inpatient floor. Pain scores, time until first
      opioid dose, total opioid requirement will be assessed and recorded. In PACU, these will be
      recorded every 15-30 minutes. On the inpatient floor, these will be recorded every 6 hours.

      Pain scores, average pain scores in first 48 hours, total opioid consumption, time until
      first opioid use, and PONV medication requirement will also be recorded. These will be
      recorded by review of the electronic medical record.

      Satisfaction scores and estimation of TAP block duration will be assessed and recorded by
      anesthesia personnel approximately 48 hours post-operatively; these will be subjective
      evaluations recorded between 24-38 hours postoperatively. The patients will be asked to
      estimate how long they felt the block lasted. For satisfaction scores, patients will rate
      their satisfaction subjectively on a scale of 1-10.

      Statistical Analysis: all demographic and clinical variables with continuous measures will be
      expressed as means and standard deviations; categorical factors will be expressed as
      proportions. For non-normal data, the medians and inter quartile ranges will be displayed.
      The distribution of the continuous factors will be examined using the Kolmogorov-Smirnov
      test. For data that are normally distributed, one-way ANOVA will be used to compare groups of
      data. For data that are not normally distributed, the Kruskal-Wallis test will be used for
      comparisons. Chi-square and Fisher's exact tests will be used to analyze categorical data.
      For all comparisons, a value of p &lt; 0.05 will be considered statistically significant.

      Statistical analyses will be performed using SAS for Windows, version 9.2. One-way ANOVA (or
      the Kruskal-Wallis test, as appropriate) will be used to compare duration of TAP block for
      the three groups. Linear regression will also be used to test the relationship between
      duration of block and dexamethasone dose, while controlling for relevant clinical and
      demographic variables.

      One-way ANOVA (or the Kruskal-Wallis test) will be used to compare the groups on
      post-operative pain scores, opioid requirements, and patient satisfaction scores.

      Statistical Power and Sample Size Estimates: Approximately 69 subjects (23 per group) are
      expected to be enrolled in this study. Given this sample size and assuming that the average
      duration of TAP block is 18 hours for the control group, 22 hours for the 2 mg of
      dexamethasone group, and 24 hours for the 4 mg of dexamethasone group, this study will have
      approximately 80.9% power to detect a difference in block duration, assuming a common
      standard deviation of 6 hours. If the variability in block time is smaller than 6 hours, this
      study will have greater power.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomly assigned to 1 of 3 groups. They will be assigned to a group prior to being brought back to the operating room. The anesthesia team in the OR will take an envelope that has which group the patient will be randomly assigned to and they will perform the TAP block with the respective dose of dexamethasone. The anesthesia team that performs the block, along with the supervising PI or sub-investigator, will be blinded to the medication in the injectate</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The anesthesia team that performs the block, along with the supervising PI or sub-investigator, will be blinded to the medication in the injectate.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>TAP c-section Block</measure>
    <time_frame>24 - 48 hours postoperatively</time_frame>
    <description>Mean duration of TAP block within 48 hrs postoperatively between the study group and the control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Pain Scores</measure>
    <time_frame>baseline to 48 hrs postoperatively</time_frame>
    <description>Collection of pain scores(VAS) every 15 minutes in PACU then every 6 hours on inpatient floor until approximately 48 hours post-operatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Pain Score</measure>
    <time_frame>48 hours postoperatively</time_frame>
    <description>Average pain score (VAS) 48 hrs postoperatively between the study group and the control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First Post-Operative Opioid Administration</measure>
    <time_frame>baseline to 48 hrs postoperatively</time_frame>
    <description>Time until first dose post-operative opioid administration between the study group and the control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Opioid consumption</measure>
    <time_frame>48hrs postoperatively</time_frame>
    <description>Average opioid consumption 48 hrs postoperatively between the study group and the control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PONV Medications</measure>
    <time_frame>baseline to 48 hrs post-operatively</time_frame>
    <description>Mean time onset use of rescue PONV medications postoperatively between the study group and the control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>48 hrs postoperatively</time_frame>
    <description>Patient satisfaction scores postoperatively between the study group and the control</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Post Surgical Pain</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of ropivacaine) and 1mL of normal saline bilaterally (control) with standard intrathecal bupivacaine and morphine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2mg Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of 0.5% ropivacaine) with 0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline split between 2 sides with standard intrathecal bupivacaine and morphine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4mg Dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 patients. Each patient will receive postoperative bilateral TAP blocks (20mL of 0.5% ropivacaine) with 20mL of 0.5% ropivacaine) and 1 mL (4mg) of dexamethasone between 2 sides with standard intrathecal bupivacaine and morphine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2mg Dexamethasone</intervention_name>
    <description>0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline</description>
    <arm_group_label>2mg Dexamethasone</arm_group_label>
    <other_name>Baycadron, Maxidex, Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4mg Dexamethasone</intervention_name>
    <description>1 mL (4mg) of dexamethasone</description>
    <arm_group_label>4mg Dexamethasone</arm_group_label>
    <other_name>Baycadron, Maxidex, Decadron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine (TAP blocks)</intervention_name>
    <description>20mL of 0% ropivacaine with 20mL of 0.5% ropivacaine</description>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>2mg Dexamethasone</arm_group_label>
    <arm_group_label>4mg Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>2mg Dexamethasone</arm_group_label>
    <arm_group_label>4mg Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine Hydrochloride</intervention_name>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_label>2mg Dexamethasone</arm_group_label>
    <arm_group_label>4mg Dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline 1ml</intervention_name>
    <description>1.0 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline 0.5ml</intervention_name>
    <description>0.5 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine</description>
    <arm_group_label>2mg Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women undergoing cesarean section delivery.

          2. Patients classified as American Society of Anesthesiology (ASA) class II or III.

               1. ASA II: mild systemic disease, pregnancy

               2. ASA III: severe systemic disease

          3. Women â‰¥ 18 years old

          4. Neuraxial anesthesia (spinal) to be used as anesthetic technique intraoperatively for
             cesarean section (this is the UAB Anesthesiology standard of care).

        Exclusion Criteria:

          1. Any patient not classified as an ASA I or II.

          2. General Anesthesia or neuraxial anesthesia with epidural used as anesthetic techniques
             for cesarean section.

          3. Allergy/intolerance to local anesthetic or steroids.

          4. Pre-existing neurological and/or anatomical deficit that would preclude regional
             block.

          5. Coexisting coagulopathy such as hemophilia or von Willebrand Disease

          6. BMI &gt; 40.

          7. Emergency Cesarean Sections
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Females undergoing cesarean section delivery</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Feinstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anesthesiology ad Perioperative Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alicia Kindred, MS</last_name>
    <phone>205-934-4711</phone>
    <email>aliciakindred@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ayesha Bryant, MSPH, MD</last_name>
    <phone>205-996-7383</phone>
    <email>asbryant@uabmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UAB Department of Anesthesiology and Perioperative Medicine</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Kindred, MS</last_name>
      <phone>205-934-4711</phone>
      <email>aliciakindred@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Ayesha Bryant, MSPH, MD</last_name>
      <phone>205-996-7383</phone>
      <email>asbryant@uabmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Powell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Froelich, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Promil Kukreja, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 13, 2017</study_first_submitted>
  <study_first_submitted_qc>March 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2017</study_first_posted>
  <last_update_submitted>September 4, 2017</last_update_submitted>
  <last_update_submitted_qc>September 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Joel Feinstein, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

